CureVac NV
(LTS:0A9E)
$
3.25
-0.051 (-1.54%)
Market Cap: 742.48 Mil
Enterprise Value: 556.60 Mil
PE Ratio: 0
PB Ratio: 1.83
GF Score: 51/100 CureVac NV (LTS:0A9E) Transcripts
- Q4 2023 CureVac NV Earnings Call TranscriptApr 24, 2024$2.39 (-8.62%)Earnings
- Q3 2023 CureVac NV Earnings Call TranscriptNov 14, 2023$5.72 (+8.24%)Earnings
- CureVac NV at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Q4 2022 CureVac NV Earnings Call TranscriptApr 25, 2023$7.65 (-2.92%)Earnings
- CureVac NV Annual Shareholders Meeting TranscriptMar 28, 2023
- CureVac NV Preliminary Phase 1 Data from Joint COVID-19 and Flu mRNA Vaccine Development Programs TranscriptJan 06, 2023
- Q3 2022 CureVac NV Earnings Call TranscriptNov 16, 2022$8.14 (+1.87%)Earnings
- CureVac NV Annual Shareholders Meeting TranscriptJun 22, 2022
- CureVac NV at JMP Securities Life Sciences Conference TranscriptJun 15, 2022
- CureVac NV at Jefferies Healthcare Conference TranscriptJun 09, 2022
- CureVac NV at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Q4 2021 CureVac NV Earnings Call TranscriptApr 28, 2022$15.6Earnings
- Q3 2021 CureVac NV Earnings Call TranscriptNov 19, 2021$41.42 (+4.85%)Earnings
- CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call TranscriptOct 12, 2021
- CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call TranscriptJul 01, 2021
- CureVac NV Updates On Clinical Trial - Corporate Call TranscriptJun 17, 2021
- Q4 2020 CureVac NV Earnings Call TranscriptApr 15, 2021Earnings
- CureVac N.V. - Special Call TranscriptFeb 05, 2021
- 1